Table 2.
Comparison of CT findings and inhaler therapy between poor responders and responders
| Total (n=166) |
Poor responders (n=109) |
Responders (n=57) |
P-value | |
|---|---|---|---|---|
| CT findings | ||||
| Number of involved lobes | 3 (2–5) | 3 (2–5) | 4 (2–5) | 0.898 |
| Involved lobe | ||||
| Right upper lobe | 98 (59) | 66 (60.6) | 32 (56.1) | 0.583 |
| Right middle lobe | 104 (62.7) | 67 (61.5) | 37 (64.9) | 0.663 |
| Right lower lobe | 109 (65.7) | 71 (65.1) | 38 (66.7) | 0.844 |
| Left upper lobe | 118 (71.1) | 77 (70.6) | 41 (71.9) | 0.862 |
| Left lower lobe | 128 (77.1) | 87 (79.8) | 41 (71.9) | 0.251 |
| Inhaler therapy | ||||
| Number of inhalers | 2 (1–2) | 2 (1–2) | 2 (1–3) | 0.076 |
| Any ICS | 88 (53) | 54 (49.5) | 34 (59.6) | 0.215 |
| LABA + LAMA ± ICS | 36 (21.7) | 18 (16.5) | 18 (31.6) | 0.025 |
| LABA ± ICS | 64 (38.6) | 46 (42.2) | 18 (31.6) | 0.182 |
| LAMA ± ICS | 66 (39.8) | 45 (41.3) | 21 (36.8) | 0.579 |
Note: Data are presented as n (%) or medians and interquartile ranges.
Abbreviations: CT, computed tomography; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.